Growth Substances - Administration & dosage
Research News and Information

Sunday, November 22, 2009

Rigorous Vibrio vulnificus soft tissue infection of the lower leg in a renal transplant patient managed by vacuum therapy and autologous growth factors.

29 Jun 2009 BACKGROUND: Vibrio vulnificus is a gram-negative marine bacterium that grows well in coastal waters. It is an opportunistic pathogen that can cause serious life-threatening infections in patients with certain health conditions. Vibrio-induced wound ... Read more...

Mecasermin: new drug. Insufficient improvement in statural growth.

30 May 2009 (1) Human insulin-like growth factor type 1 (IGF-1) is the main effector of growth hormone action. Primary IGF-1 deficiency is a rare disease, mainly resulting in very short stature; (2) Mecasermin is a recombinant IGF-1 marketed for this indication ... Read more...

From natural bone grafts to tissue engineering therapeutics: Brainstorming on pharmaceutical formulative requirements and challenges.

30 Mar 2009 Tissue engineering is an emerging multidisciplinary field of investigation focused on the regeneration of diseased or injured tissues through the delivery of appropriate molecular and mechanical signals. Therefore, bone tissue engineering covers all ... Read more...

Latest indexed articles for 'Growth Substances - Administration & dosage'

These are the very latest articles for this heading:

• Rigorous Vibrio vulnificus soft tissue infection of the lower leg in a renal transplant patient managed by vacuum therapy and autologous growth factors. 29 Jun 2009
• Mecasermin: new drug. Insufficient improvement in statural growth. 30 May 2009
• From natural bone grafts to tissue engineering therapeutics: Brainstorming on pharmaceutical formulative requirements and challenges. 30 Mar 2009
• Hyaluronan based porous nano-particles enriched with growth factors for the treatment of ulcers: a placebo-controlled study. 28 Aug 2008
• Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. 24 Aug 2008
• Microarray analysis of mitogenic effects of T3 on the rat liver. 18 Aug 2008
• Addition of nitric oxide through nitric oxide-paracetamol enhances healing rat achilles tendon. 6 May 2008
• Comparison of alternative beef production systems based on forage finishing or grain-forage diets with or without growth promotants: 2. Meat quality, fatty acid composition, and overall palatability. 26 Mar 2008
• Effects of human amniotic fluid on fracture healing in rat tibia. 16 Mar 2008
• Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. 13 Mar 2008
• Laser in situ keratomileusis flap necrosis after trigeminal nerve palsy. 29 Sep 2007
• Effects of an illicit cocktail on serum immunoglobulins, lymphocyte proliferation and cytokine gene expression in the veal calf. 6 Sep 2007
• Growth-promotant implants: managing the tools. 29 Jun 2007
• Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. 20 Jun 2007
• Starch-based microparticles as vehicles for the delivery of active platelet-derived growth factor. 30 May 2007
• A study of the factors that influence consumer attitudes toward beef products using the conjoint market analysis tool. 23 May 2007
• [The use of platelet rich plasma (PRP) and platelet rich fibrin (PRP) extracts in dental implantology and oral surgery] 30 Dec 2006
• Improving culture conditions for temporomandibular joint disc tissue engineering. 30 Dec 2006
• Growth factors and stroke. 29 Sep 2006
• A novel skin cream containing a mixture of human growth factors and cytokines for the treatment of adverse events associated with photodynamic therapy. 30 Aug 2006

See a longer list of these articles.

Technical information about 'Growth Substances'

Definition: Signal molecules that are involved in the control of cell growth and differentiation.

Registry Number: 0

Descriptor UI: D006133

Alternative terms: Growth Substances; Mitogens, Endogenous; Endogenous Mitogens;

Related Mesh Headings: Receptors, Growth Factor;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.696.377;

Technical Notes: general or unspecified: prefer specifics